National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pembrolizumab (Keytruda ®) for Urothelial Carcinoma 1L

Pembrolizumab (Keytruda®) is indicated for the first-line treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.


NCPE Assessment Process Complete
Rapid review commissioned 06/12/2017
Rapid review completed 21/12/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended


Following an amendment of the product license by the EMA, a new rapid review was commissioned by the HSE.
Rapid review commissioned 21/06/2018
Rapid review received 10/07/2018
Rapid review completed 27/07/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies


The HSE has approved reimbursement following confidential price negotiations – February 2021.